Skip to main content
SpringerLink
Log in

Treatment Goals in Neovascular Glaucoma

  • Chapter
  • First Online:
Neovascular Glaucoma

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 228 Accesses

Abstract

Vision loss in neovascular glaucoma is multifactorial and typically driven by both the underlying ischemic retinal disease as well as the optic nerve damage resulting from elevated intraocular pressure. Management involves suppressing the source of the neovascularization and controlling the intraocular pressure. Treatment goals vary according to several factors, including disease stage, clinical presentation, and most importantly visual potential. The assessment of visual potential, which is frequently confounded by other transient causes of vision loss in neovascular glaucoma, is critical to guiding surgical treatment and overall management goals. Eyes with good visual potential benefit from aggressive treatment to preserve vision. In contrast, the main treatment goal in eyes with minimal visual potential is pain control and comfort. Long-term management after initial intervention and stabilization involves the treatment of a secondary chronic angle-closure glaucoma. Baseline workup with visual field testing and optic nerve imaging, which is frequently confounded by concurrent retinal disease, can help clinicians assess the degree of optic nerve damage, potentially establish a target intraocular pressure, and longitudinally monitor for glaucoma progression. Chronic management of the underlying retinal disease and other systemic conditions is essential to halting the disease process and maintaining functional vision.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cronemberger S, Lourenco LF, Silva LC, Calixto N, Pires MC. Prognosis of glaucoma in relation to blindness at a university hospital. Arq Bras Oftalmol. 2009;72(2):199–204.

    Article  Google Scholar 

  2. Lazcano-Gomez G, J RS, Lynch A, L NB, Martinez K, Turati M, et al. Neovascular glaucoma: a retrospective review from a tertiary eye care center in Mexico. J Curr Glaucoma Pract. 2017;11(2):48–51.

    Article  Google Scholar 

  3. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470–85.

    Article  Google Scholar 

  4. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol. 2009;24(2):113–21.

    Article  Google Scholar 

  5. SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015;43(9):803–7.

    Article  Google Scholar 

  6. Teich SA, Walsh JB. A grading system for iris neovascularization. Prognostic implications for treatment. Ophthalmology. 1981;88(11):1102–6.

    Article  CAS  Google Scholar 

  7. Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2020;2(2):Cd007920.

    Google Scholar 

  8. Sánchez-Tabernero S, Juberías JR, Artells N, Crespo-Millas S, Meneses C, Muñoz-Moreno MF, et al. Management and systemic implications of diabetic neovascular glaucoma. Ophthalmic Res. 2019;62(2):111–5.

    Article  Google Scholar 

  9. Risk factors for suprachoroidal hemorrhage after filtering surgery. The fluorouracil filtering surgery study group. Am J Ophthalmol. 1992;113(5):501–7.

    Google Scholar 

  10. Jeganathan VS, Ghosh S, Ruddle JB, Gupta V, Coote MA, Crowston JG. Risk factors for delayed suprachoroidal haemorrhage following glaucoma surgery. Br J Ophthalmol. 2008;92(10):1393–6.

    Article  CAS  Google Scholar 

  11. Learned D, Eliott D. Management of delayed suprachoroidal hemorrhage after glaucoma surgery. Semin Ophthalmol. 2018;33(1):59–63.

    Article  Google Scholar 

  12. Liao N, Li C, Jiang H, Fang A, Zhou S, Wang Q. Neovascular glaucoma: a retrospective review from a tertiary center in China. BMC Ophthalmol. 2016;16:14.

    Article  Google Scholar 

  13. Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2016;55:196–204.

    Article  Google Scholar 

  14. Wen JC, Chen CL, Rezaei KA, Chao JR, Vemulakonda A, Luttrell I, et al. Optic nerve head perfusion before and after intravitreal antivascular growth factor injections using optical coherence tomography-based microangiography. J Glaucoma. 2019;28(3):188–93.

    Article  Google Scholar 

  15. Kim ES, Yu SY, Han SB, Kim M. Decompression retinopathy after intravitreal bevacizumab and anterior chamber paracentesis in a patient with neovascular glaucoma. Indian J Ophthalmol. 2016;64(11):861–3.

    Article  Google Scholar 

  16. Sandinha MT, Kotagiri AK, Owen RI, Geenen C, Steel DH. Accuracy of B-scan ultrasonography in acute fundus obscuring vitreous hemorrhage using a standardized scanning protocol and a dedicated ophthalmic ultrasonographer. Clin Ophthalmol. 2017;11:1365–70.

    Article  Google Scholar 

  17. Browning DJ, Buckley EG. Reliability of brightness comparison testing in predicting afferent pupillary defects. Arch Ophthalmol. 1988;106(3):341–3.

    Article  CAS  Google Scholar 

  18. Takihara Y, Inatani M, Fukushima M, Iwao K, Iwao M, Tanihara H. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol. 2009;147(5):912–8, 8.e1.

    Google Scholar 

  19. Budenz DL, Barton K, Gedde SJ, Feuer WJ, Schiffman J, Costa VP, et al. Five-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2015;122(2):308–16.

    Article  Google Scholar 

  20. Cheng Y, Liu XH, Shen X, Zhong YS. Ahmed valve implantation for neovascular glaucoma after 23-gauge vitrectomy in eyes with proliferative diabetic retinopathy. Int J Ophthalmol. 2013;6(3):316–20.

    Google Scholar 

  21. Gedde SJ. Personal communication regarding the results of the Ahmed Baerveldt comparison study. Miami: Bascom Palmer Eye Institute; 2021.

    Google Scholar 

  22. Shalaby WS, Myers JS, Razeghinejad R, Katz LJ, Pro M, Dale E, et al. Outcomes of valved and nonvalved tube shunts in neovascular glaucoma. Ophthalmol Glaucoma. 2020.

    Google Scholar 

  23. Shchomak Z, Cordeiro Sousa D, Leal I, Abegão PL. Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019;257(6):1079–89.

    Article  Google Scholar 

  24. Simsek T, Bilgeç MD. Ahmed glaucoma valve implantation versus suprachoroidal silicone tube implantation following the injection of bevacizumab into the anterior chamber in patients with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(4):799–804.

    Article  CAS  Google Scholar 

  25. Suda M, Nakanishi H, Akagi T, Murakami T, Suzuma K, Suda K, et al. Baerveldt or Ahmed glaucoma valve implantation with pars plana tube insertion in Japanese eyes with neovascular glaucoma: 1-year outcomes. Clin Ophthalmol. 2018;12:2439–49.

    Article  Google Scholar 

  26. Ndulue JK, Rahmatnejad K, Sanvicente C, Wizov SS, Moster MR. Evolution of cyclophotocoagulation. J Ophthalmic Vis Res. 2018;13(1):55–61.

    Article  Google Scholar 

  27. Sarrafpour S, Saleh D, Ayoub S, Radcliffe NM. Micropulse transscleral cyclophotocoagulation: a look at long-term effectiveness and outcomes. Ophthalmol Glaucoma. 2019;2(3):167–71.

    Article  Google Scholar 

  28. Schrieber C, Liu Y. Choroidal effusions after glaucoma surgery. Curr Opin Ophthalmol. 2015;26(2):134–42.

    Article  Google Scholar 

  29. Hwang HB, Han JW, Yim HB, Lee NY. Beneficial effects of adjuvant intravitreal bevacizumab injection on outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma: systematic literature review. J Ocul Pharmacol Ther. 2015;31(4):198–203.

    Article  CAS  Google Scholar 

  30. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol. 2004;15(2):119–26.

    Article  Google Scholar 

  31. Idowu OO, Ashraf DC, Kalin-Hajdu E, Ryan MC, Kersten RC, Vagefi MR. Efficacy of care for blind painful eyes. Ophthalmic Plast Reconstr Surg. 2019;35(2):182–6.

    Article  Google Scholar 

  32. Blanc JP, Molteno AC, Fuller JR, Bevin TH, Herbison P. Life expectancy of patients with neovascular glaucoma drained by Molteno implants. Clin Exp Ophthalmol. 2004;32(4):360–3.

    Article  Google Scholar 

  33. Nielsen NV. The prevalence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol. 1983;61(4):662–72.

    Article  CAS  Google Scholar 

  34. Ohrt V. The frequency of rubeosis iridis in diabetic patients. Acta Ophthalmol. 1971;49(2):301–7.

    Article  CAS  Google Scholar 

  35. Yin X, Li J, Zhang B, Lu P. Association of glaucoma with risk of retinal vein occlusion: a meta-analysis. Acta Ophthalmol. 2019;97(7):652–9.

    Article  Google Scholar 

  36. Brusini P, Johnson CA. Staging functional damage in glaucoma: review of different classification methods. Surv Ophthalmol. 2007;52(2):156–79.

    Article  Google Scholar 

  37. Tan NYQ, Tham YC, Koh V, Nguyen DQ, Cheung CY, Aung T, et al. The effect of testing reliability on visual field sensitivity in normal eyes: the Singapore Chinese eye study. Ophthalmology. 2018;125(1):15–21.

    Article  CAS  Google Scholar 

  38. Kotowski J, Wollstein G, Folio LS, Ishikawa H, Schuman JS. Clinical use of OCT in assessing glaucoma progression. Ophthalmic Surg Lasers Imaging. 2011;42(Suppl 0):S6–14.

    Google Scholar 

  39. Patel PJ, Chen FK, da Cruz L, Tufail A. Segmentation error in stratus optical coherence tomography for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(1):399–404.

    Article  Google Scholar 

  40. Hwang DJ, Lee EJ, Lee SY, Park KH, Woo SJ. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles. Invest Ophthalmol Vis Sci. 2014;55(7):4213–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Humberto Salazar & Swarup S. Swaminathan

Authors
  1. Humberto Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Swarup S. Swaminathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Swarup S. Swaminathan .

Editor information

Editors and Affiliations

  1. Ophthalmology and Visual Science, University of Chicago, Chicago, IL, USA

    Mary Qiu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Salazar, H., Swaminathan, S.S. (2022). Treatment Goals in Neovascular Glaucoma. In: Qiu, M. (eds) Neovascular Glaucoma. Essentials in Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-031-11720-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-11720-6_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-11719-0

  • Online ISBN: 978-3-031-11720-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation